{"id":2545427,"date":"2023-06-09T10:00:32","date_gmt":"2023-06-09T14:00:32","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/panel-discussion-on-testing-and-labeling-for-minor-cannabinoid-products-moderated-by-paul-coble-at-ncia-event-on-june-13th\/"},"modified":"2023-06-09T10:00:32","modified_gmt":"2023-06-09T14:00:32","slug":"panel-discussion-on-testing-and-labeling-for-minor-cannabinoid-products-moderated-by-paul-coble-at-ncia-event-on-june-13th","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/panel-discussion-on-testing-and-labeling-for-minor-cannabinoid-products-moderated-by-paul-coble-at-ncia-event-on-june-13th\/","title":{"rendered":"Panel Discussion on Testing and Labeling for “Minor Cannabinoid” Products Moderated by Paul Coble at NCIA Event on June 13th"},"content":{"rendered":"

On June 13th, the National Cannabis Industry Association (NCIA) hosted a panel discussion on testing and labeling for “minor cannabinoid” products. The event was moderated by Paul Coble, a former member of the Raleigh City Council and current Vice President of Government Affairs at the NCIA.<\/p>\n

Minor cannabinoids are compounds found in the cannabis plant that are not as well-known as THC and CBD. These include compounds like CBG, CBN, and THCV, which have been shown to have potential therapeutic benefits but are not yet widely understood by consumers.<\/p>\n

The panel discussion focused on the importance of testing and labeling these minor cannabinoid products to ensure that consumers are getting accurate information about what they are buying. This is particularly important given the lack of regulation in the cannabis industry, which can lead to inconsistencies in product quality and labeling.<\/p>\n

One of the key points made during the discussion was the need for standardized testing methods for minor cannabinoids. Currently, there is no standardized method for testing these compounds, which can lead to inconsistencies in product quality and labeling. The panelists emphasized the importance of developing standardized testing methods to ensure that consumers are getting accurate information about the products they are buying.<\/p>\n

Another important topic discussed during the panel was the need for clear labeling of minor cannabinoid products. This includes not only accurate information about the cannabinoid content of the product, but also information about any other ingredients or additives that may be present. Clear labeling can help consumers make informed decisions about which products to buy and can also help to build trust in the industry.<\/p>\n

Overall, the panel discussion on testing and labeling for minor cannabinoid products was an important step in promoting transparency and accountability in the cannabis industry. By emphasizing the need for standardized testing methods and clear labeling, the panelists highlighted the importance of ensuring that consumers have access to accurate information about the products they are buying. As the cannabis industry continues to grow and evolve, events like this will be crucial in promoting responsible practices and building trust with consumers.<\/p>\n